• CMS revenue contribution: The Custom Manufacturing Solutions (CMS) segment now accounts for over 60% of total revenues, supported by more than 10 commercial molecules with 3 to 4 key products driving primary growth.
• Revenue lumpiness: Quarterly volatility in the CMS business is driven by small-to-mid volume niche molecules where customers schedule manufacturing campaigns only once or twice a year rather than every quarter.
• Financial outlook: Management considers 15–20% annual revenue growth and a 25% EBITDA margin reasonable baselines over the medium term, though favorable conditions can yield EBITDA margins of 30% or higher.
• Strategic acquisition plans: Neuland is evaluating strategic, capability-focused M&A opportunities rather than capacity additions, aiming to establish a direct presence in the US to be closer to innovator clients.